Systematic Review of Peri-operative Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma

Overview

Journal HPB (Oxford)

Publisher Elsevier

Specialty Gastroenterology

Date 2016 Aug 4

PMID 27485059

Citations 13

Authors

Wilson Petrushnko

Justin S Gundara

Philip R de Reuver

Greg OGrady

Jaswinder S Samra

Anubhav Mittal

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) continues to be associated with a poor prognosis. This systematic review aimed to summarize the literature regarding potential prognostic biomarkers to facilitate validation studies and clinical application.

Methods: A systematic review was performed (2004-2014) according to PRISMA guidelines. Studies were ranked using REMARK criteria and the following outcomes were examined: overall/disease free survival, nodal involvement, tumour characteristics, metastasis, recurrence and resectability.

Results: 256 biomarkers were identified in 158 studies. 171 biomarkers were assessed with respect to overall survival: urokinase-type plasminogen activator receptor, atypical protein kinase C and HSP27 ranked the highest. 33 biomarkers were assessed for disease free survival: CD24 and S100A4 were the highest ranking. 17 biomarkers were identified for lymph node involvement: Smad4/Dpc4 and FOXC1 ranked highest. 13 biomarkers were examined for tumour grade: mesothelin and EGFR were the highest ranking biomarkers. 10 biomarkers were identified for metastasis: p16 and sCD40L were the highest ranking. 4 biomarkers were assessed resectability: sCD40L, s100a2, Ca 19-9, CEA.

Conclusion: This review has identified and ranked specific biomarkers that should be a primary focus of ongoing validation and clinical translational work in PDAC.

Citing Articles

Uncovering the clinicopathological features of early recurrence after surgical resection of pancreatic cancer.

Chon H, Lee H, Sung Y, Tae Y, Park C, Leem G Sci Rep. 2024; 14(1):2942.

PMID: 38316853 PMC: 10844252. DOI: 10.1038/s41598-024-52909-4.

Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma.

Ermiah E, Eddfair M, Abdulrahman O, Elfagieh M, Jebriel A, Al-Sharif M Mol Clin Oncol. 2022; 17(2):126.

PMID: 35832472 PMC: 9264325. DOI: 10.3892/mco.2022.2559.

S100 Proteins in Pancreatic Cancer: Current Knowledge and Future Perspectives.

Wu Y, Zhou Q, Guo F, Chen M, Tao X, Dong D Front Oncol. 2021; 11:711180.

PMID: 34527585 PMC: 8435722. DOI: 10.3389/fonc.2021.711180.

Development and validation of a four-lipid metabolism gene signature for diagnosis of pancreatic cancer.

Ye Y, Chen Z, Shen Y, Qin Y, Wang H FEBS Open Bio. 2021; 11(11):3153-3170.

PMID: 33386701 PMC: 8564347. DOI: 10.1002/2211-5463.13074.

Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma?.

Mattevi C, Garnier J, Marchese U, Ewald J, Gilabert M, Poizat F BMC Surg. 2020; 20(1):176.

PMID: 32758203 PMC: 7430808. DOI: 10.1186/s12893-020-00835-3.

References

Juuti A, Nordling S, Lundin J, Louhimo J, Haglund C . Syndecan-1 expression--a novel prognostic marker in pancreatic cancer. Oncology. 2005; 68(2-3):97-106. DOI: 10.1159/000085702. View

Biankin A, Kench J, Colvin E, Segara D, Scarlett C, Nguyen N . Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology. 2009; 137(2):558-68, 568.e1-11. DOI: 10.1053/j.gastro.2009.04.009. View

Liang J, Wang H, Rashid A, Tan T, Hwang R, Hamilton S . Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res. 2008; 14(21):7043-9. DOI: 10.1158/1078-0432.CCR-08-0381. View

Guo S, Jing W, Hu X, Zhou X, Liu L, Zhu M . Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients. Int J Cancer. 2013; 134(6):1369-78. DOI: 10.1002/ijc.28471. View

An X, Li Y, Lin X, Wang F, Feng F, Xu R . [Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy]. Ai Zheng. 2009; 28(3):286-91. View

Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Sakai H . MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol. 2010; 17(12):3120-8. DOI: 10.1245/s10434-010-1188-8. View

Katz M, Marsh R, Herman J, Shi Q, Collison E, Venook A . Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013; 20(8):2787-95. PMC: 5600517. DOI: 10.1245/s10434-013-2886-9. View

Shin S, Kim S, Hong S, Kim Y, Song K, Park K . Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas. 2013; 42(2):216-22. DOI: 10.1097/MPA.0b013e31825b6ab0. View

Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K . High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Int J Oncol. 2011; 38(3):629-41. DOI: 10.3892/ijo.2011.908. View

10.

Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Fujita H, Nakata K . S100A4 mRNA is a diagnostic and prognostic marker in pancreatic carcinoma. J Gastrointest Surg. 2009; 13(10):1852-8. DOI: 10.1007/s11605-009-0978-4. View

11.

Yuzawa S, Kano M, Einama T, Nishihara H . PDGFRβ expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker. Med Oncol. 2012; 29(4):2824-30. DOI: 10.1007/s12032-012-0193-0. View

12.

Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y . Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg. 2013; 258(2):336-46. DOI: 10.1097/SLA.0b013e3182827a65. View

13.

Abramson M, Jazag A, Van der Zee J, Whang E . The molecular biology of pancreatic cancer. Gastrointest Cancer Res. 2009; 1(4 Suppl 2):S7-S12. PMC: 2666839. View

14.

Barton J, Bois J, Sarr M, Wood C, Qin R, Thomsen K . Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg. 2009; 13(11):2050-8. DOI: 10.1007/s11605-009-0849-z. View

15.

Pine J, Fusai K, Young R, Sharma D, Davidson B, Menon K . Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol. 2009; 35(6):605-10. DOI: 10.1016/j.ejso.2008.12.002. View

16.

Berger A, Meszoely I, Ross E, Watson J, Hoffman J . Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004; 11(7):644-9. DOI: 10.1245/ASO.2004.11.025. View

17.

Dima S, Tanase C, Albulescu R, Herlea V, Chivu-Economescu M, Purnichescu-Purtan R . An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas. 2012; 41(7):1001-7. DOI: 10.1097/MPA.0b013e3182546e13. View

18.

Fong D, Moser P, Kasal A, Seeber A, Gastl G, Martowicz A . Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer. Histopathology. 2013; 64(5):683-92. DOI: 10.1111/his.12307. View

19.

Roselli M, Mineo T, Basili S, Mariotti S, Martini F, Bellotti A . Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost. 2003; 89(1):177-84. View

20.

Hildenbrand R, Niedergethmann M, Marx A, Belharazem D, Allgayer H, Schleger C . Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am J Pathol. 2009; 174(6):2246-53. PMC: 2684189. DOI: 10.2353/ajpath.2009.080785. View